Jeremie Calais
Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.
Overview
Jeremie Calais is Associate Professor and Director of the Clinical Research Program in the Ahmanson Translational Theranostics Division at UCLA, part of the UCLA Jonsson Comprehensive Cancer Center. A nuclear medicine physician specialising in PSMA PET and radioligand therapy, he leads prospective PSMA PET and PSMA radioligand therapy trials, including the head-to-head comparison of PSMA PET with fluciclovine PET and dosimetry research. His papers include the Lancet Oncology comparative imaging trial of 18F-fluciclovine and 68Ga-PSMA-11 PET-CT in early biochemical recurrence after prostatectomy and the Journal of Nuclear Medicine RESIST-PC phase 2 trial of 177Lu-PSMA-617 in the UCLA cohort. His work centres on prostate cancer theranostics.
Similar pages
not linked directly; found by shared links- PersonJohannes Czernin
Shares UCLA Jonsson Comprehensive Cancer Center, PSMA, PSMA PET, Gallium-68.
- PersonPeter Bartenstein
Shares PSMA, PSMA PET, Fluorine-18, Gallium-68.
- PairingPSMA PET → PSMA radioligand therapy
Shares Appropriate use criteria for prostate-specific membrane antigen (PSMA) PET imaging, PSMA, PSMA PET, Fluorine-18.
- PersonRahul Aggarwal
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- AgentFlotufolastat F-18
Shares PSMA, PSMA PET, Fluorine-18, Gallium-68.
- CompanyBracco Imaging
Shares PSMA, PSMA PET, Fluorine-18, Prostate cancer.
- PersonThomas A. Hope
Shares PSMA, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- IdeaBispecific PSMA/GRPR radioligands for discordant prostate cancer lesions
Shares PSMA, PSMA PET, Gallium-68, Lutetium-177.